New US FDA Genetic Metabolic Adcomm Needs More Candidates

 
• By Derrick Gingery

Given the enthusiasm for the new advisory committee within the rare disease community, the need for an extended deadline is somewhat surprising. FDA has not yet determined when the chair and members of the new panel will be named.

Submit nomination
The FDA gave more time for GeMDAC candidates to submit materials. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers